Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin + Bu/Cy Conditioning for High Risk AML/MDS
NCT02221310Phase 2Completed
- Sponsor
- New York Medical College
- Start
- Dec 2011
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by New York Medical College. Primary endpoint: Response rate at 1 year. Started Dec 2011; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02221310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221310.